Exelixis vs. Cipla: Cancer Drug Patent Dispute Dismissed
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Exelixis, Inc. v. Cipla Limited and Cipla USA, Inc. |
| Case Number | 1:23-cv-00287 (D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | Mar 2023 – Jul 2024 1 year 4 months |
| Outcome | Dismissed Without Prejudice |
| Patents at Issue | |
| Accused Products | Cipla’s generic cabozantinib malate products |
Case Overview
The Parties
⚖️ Plaintiff
California-based oncology-focused biopharmaceutical company known for developing cabozantinib (Cabometyx®), a multi-kinase inhibitor for cancer treatment.
🛡️ Defendant
Global generic pharmaceutical manufacturer headquartered in Mumbai, India, with a U.S. commercial arm distributing products in American markets.
Patents at Issue
This closely watched pharmaceutical patent dispute involved five patents protecting the malate salt formulation of cabozantinib, a blockbuster oncology compound used in the treatment of cancer. These patents form a layered defensive perimeter around the active pharmaceutical ingredient (API).
- • US8877776B2 — Directed to the (L)-malate salt of cabozantinib’s chemical compound
- • US11091440B2 — Covering malate salt formulations and crystalline forms for cancer treatment
- • US11298349B2 — Crystalline form claims with therapeutic applications
- • US11098015B2 — Additional salt and crystalline form coverage
- • US11091439B2 — Processes for preparing quinoline-based compounds and pharmaceutical compositions
Developing a similar drug formulation?
Check if your pharmaceutical product might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The parties filed a **joint stipulation of dismissal without prejudice** pursuant to Fed. R. Civ. P. 41, with each party bearing its own costs and attorneys’ fees. No damages were awarded. No injunctive relief was granted or denied on the merits. No judicial findings on patent validity or infringement were issued.
This outcome reflects a broader industry pattern in **pharmaceutical patent infringement** cases where generic manufacturers and innovator companies navigate ANDA-related disputes through strategic settlement or voluntary withdrawal rather than courtroom adjudication.
Key Legal Issues
The operative cause was an **infringement action**, most likely triggered by Cipla’s filing of an Abbreviated New Drug Application (ANDA) with the FDA. Under the **Hatch-Waxman Act**, an ANDA filing containing a Paragraph IV certification constitutes a technical act of patent infringement, enabling the brand manufacturer to initiate litigation within 45 days and trigger a 30-month regulatory stay.
Critically, dismissal “without prejudice” preserves Exelixis’s right to refile infringement claims against Cipla should circumstances warrant — a strategically significant preservation of future rights. Because the case dismissed without prejudice and without judicial merits ruling, it carries **no direct precedential value** on the substantive patent questions involving cabozantinib malate salt claims, polymorph validity, or process patent scope.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in this therapeutic space
- See which companies are most active in oncology IP
- Understand patent thicket strategies
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your compound structure or formulation details
- AI identifies potentially blocking pharmaceutical patents
- Get actionable risk assessment report
High Risk Area
Cabozantinib malate salt forms
5 Patents Asserted
Covering compound, polymorphs, process
ANDA Pathway
Hatch-Waxman implications
✅ Key Takeaways
Stipulated dismissal without prejudice preserves all future enforcement rights — a strategically valuable outcome for patent holders.
Search related case law →Five-patent assertion across compound, salt, polymorph, and process claims is the pharmaceutical IP standard for blockbuster drug defense.
Explore precedents →Delaware District Court under Chief Judge Andrews remains premier venue for complex pharma patent disputes.
View court statistics →Frequently Asked Questions
Five U.S. patents were asserted: US8877776B2, US11091440B2, US11298349B2, US11098015B2, and US11091439B2, collectively covering cabozantinib malate salt forms, crystalline polymorphs, and preparative processes.
The parties stipulated to dismissal without prejudice under Fed. R. Civ. P. 41, with each party bearing its own costs. No merits rulings on validity or infringement were issued by the court.
It reinforces the strategic value of multi-layered patent portfolios in Hatch-Waxman disputes and the frequency with which such cases resolve through negotiated outcomes before trial.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER — Case No. 1:23-cv-00287 (D. Del.)
- USPTO Patent Full-Text Database
- U.S. Food and Drug Administration (FDA) — ANDA Information
- Cornell Legal Information Institute — Hatch-Waxman Act
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.